11/20
12:04 am
mcrb
Seres Therapeutics, Inc. (NASDAQ: MCRB) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
High
Report
Seres Therapeutics, Inc. (NASDAQ: MCRB) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
11/19
02:32 pm
mcrb
The Athlete's Edge: How One Biotech Startup Is Mining Elite Athletes' Gut Bacteria To Create Next-Gen Probiotics [Forbes]
Low
Report
The Athlete's Edge: How One Biotech Startup Is Mining Elite Athletes' Gut Bacteria To Create Next-Gen Probiotics [Forbes]
11/14
11:13 am
mcrb
Seres Therapeutics, Inc. (NASDAQ: MCRB) had its "buy" rating re-affirmed by analysts at Canaccord Genuity Group Inc.. They now have a $10.00 price target on the stock.
Low
Report
Seres Therapeutics, Inc. (NASDAQ: MCRB) had its "buy" rating re-affirmed by analysts at Canaccord Genuity Group Inc.. They now have a $10.00 price target on the stock.
11/14
02:21 am
mcrb
Seres Therapeutics Inc (MCRB) Q3 2024 Earnings Call Highlights: Strategic Moves and Clinical ... [Yahoo! Finance]
Low
Report
Seres Therapeutics Inc (MCRB) Q3 2024 Earnings Call Highlights: Strategic Moves and Clinical ... [Yahoo! Finance]
11/13
07:42 pm
mcrb
Seres Therapeutics, Inc. (NASDAQ: MCRB) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $1.25 price target on the stock.
Low
Report
Seres Therapeutics, Inc. (NASDAQ: MCRB) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $1.25 price target on the stock.
11/13
10:31 am
mcrb
Seres Therapeutics, Inc. (MCRB) Q3 2024 Earnings Call Transcript [Seeking Alpha]
High
Report
Seres Therapeutics, Inc. (MCRB) Q3 2024 Earnings Call Transcript [Seeking Alpha]
11/13
07:08 am
mcrb
Seres Therapeutics GAAP EPS of -$0.33 misses by $0.25 Nov. 13, 2024 7:05 AM ET By: Deepa Sarvaiya , SA News Editor [Seeking Alpha]
High
Report
Seres Therapeutics GAAP EPS of -$0.33 misses by $0.25 Nov. 13, 2024 7:05 AM ET By: Deepa Sarvaiya , SA News Editor [Seeking Alpha]
11/13
07:00 am
mcrb
Seres Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates
High
Report
Seres Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates
11/6
07:00 am
mcrb
Seres Therapeutics to Announce Third Quarter 2024 Financial Results and Business Updates on November 13, 2024
Medium
Report
Seres Therapeutics to Announce Third Quarter 2024 Financial Results and Business Updates on November 13, 2024
10/24
07:16 am
mcrb
Seres Therapeutics, Inc. (NASDAQ: MCRB) was downgraded by analysts at JPMorgan Chase & Co. from a "neutral" rating to an "underweight" rating.
Medium
Report
Seres Therapeutics, Inc. (NASDAQ: MCRB) was downgraded by analysts at JPMorgan Chase & Co. from a "neutral" rating to an "underweight" rating.
10/8
09:55 am
mcrb
Institutions along with retail investors who hold considerable shares inSeres Therapeutics, Inc. (NASDAQ:MCRB) come under pressure; lose 12% of holdings value [Yahoo! Finance]
Medium
Report
Institutions along with retail investors who hold considerable shares inSeres Therapeutics, Inc. (NASDAQ:MCRB) come under pressure; lose 12% of holdings value [Yahoo! Finance]
10/1
05:06 pm
mcrb
Seres Therapeutics files for resale of common stock by holder [Seeking Alpha]
Low
Report
Seres Therapeutics files for resale of common stock by holder [Seeking Alpha]
9/30
05:21 pm
mcrb
Seres Therapeutics Announces Completion of VOWST™ Asset Sale to Société des Produits Nestlé S.A [Yahoo! Finance]
Low
Report
Seres Therapeutics Announces Completion of VOWST™ Asset Sale to Société des Produits Nestlé S.A [Yahoo! Finance]
9/30
05:15 pm
mcrb
Seres Therapeutics Announces Completion of VOWST™ Asset Sale to Société des Produits Nestlé S.A
Low
Report
Seres Therapeutics Announces Completion of VOWST™ Asset Sale to Société des Produits Nestlé S.A
9/27
03:26 pm
mcrb
Seres Therapeutics Stockholders Issue Open Letter to Board of Directors Regarding Reported Engagement With Nestlé
Low
Report
Seres Therapeutics Stockholders Issue Open Letter to Board of Directors Regarding Reported Engagement With Nestlé
9/26
04:01 pm
mcrb
Seres Therapeutics Stockholders Approve Sale of VOWST™ to Nestlé Health Science; Sale Expected to Close on September 30
High
Report
Seres Therapeutics Stockholders Approve Sale of VOWST™ to Nestlé Health Science; Sale Expected to Close on September 30
9/13
03:35 pm
mcrb
Seres Therapeutics, Inc. (NASDAQ: MCRB) had its "buy" rating re-affirmed by analysts at Canaccord Genuity Group Inc.. They now have a $10.00 price target on the stock.
Low
Report
Seres Therapeutics, Inc. (NASDAQ: MCRB) had its "buy" rating re-affirmed by analysts at Canaccord Genuity Group Inc.. They now have a $10.00 price target on the stock.
9/13
07:00 am
mcrb
Seres Therapeutics to Participate in Cantor 2024 Global Healthcare Conference
Medium
Report
Seres Therapeutics to Participate in Cantor 2024 Global Healthcare Conference
9/12
07:07 am
mcrb
Seres Therapeutics Reports SER-155 Phase 1b Placebo-Controlled Cohort 2 Study Safety and Clinical Results in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT) [Yahoo! Finance]
Medium
Report
Seres Therapeutics Reports SER-155 Phase 1b Placebo-Controlled Cohort 2 Study Safety and Clinical Results in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT) [Yahoo! Finance]
9/12
07:00 am
mcrb
Seres Therapeutics Reports SER-155 Phase 1b Placebo-Controlled Cohort 2 Study Safety and Clinical Results in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT)
Medium
Report
Seres Therapeutics Reports SER-155 Phase 1b Placebo-Controlled Cohort 2 Study Safety and Clinical Results in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT)
9/9
08:50 am
mcrb
Emerging microbiome market – unlocking new frontiers [Yahoo! Finance]
Medium
Report
Emerging microbiome market – unlocking new frontiers [Yahoo! Finance]
9/4
11:33 am
mcrb
After Plunging -22.45% in 4 Weeks, Here's Why the Trend Might Reverse for Seres Therapeutics (MCRB) [Yahoo! Finance]
Low
Report
After Plunging -22.45% in 4 Weeks, Here's Why the Trend Might Reverse for Seres Therapeutics (MCRB) [Yahoo! Finance]